Literature DB >> 2438993

Reversible and irreversible nodal dysfunction in diabetic neuropathy.

T Brismar, A A Sima, D A Greene.   

Abstract

Acute reversible diabetic nerve dysfunction has been associated with a reversible myo-inositol-related (Na+ + K+)-ATPase defect, while poorly reversible chronic nerve dysfunction correlates with progressive axoglial dysjunction of peripheral nerve. The causal relationships between biochemical and neuroanatomical abnormalities and those of nodal membrane function are not known. Nodal clamp examinations were carried out in the sciatic nerve of diabetic BB-rats to elucidate the events underlying diabetic nerve dysfunctions and how these relate to metabolic and structural defects of diabetic nerve. With increasing duration of diabetes, there was a progressive decline in nodal action potentials attributable to decreased Na+ permeability and a decrease in the membranous Na+ gradient. Vigorous insulin therapy in short-term (6-week) diabetic BB-rats normalized the Na+-permeability defect and the membranous Na+ gradient. These defects did not reverse in long-term (24-week) diabetic animals subjected to the same treatment. This poorly reversible nodal dysfunction accounts for the not readily reversible conduction defect in chronic diabetes and is probably directly related to irreversible axoglial dysjunction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438993     DOI: 10.1002/ana.410210515

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W-rat.

Authors:  A A Sima; W X Zhang; P V Cherian; S Chakrabarti
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

2.  Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.

Authors:  A A Sima; V Nathaniel; V Bril; T A McEwen; D A Greene
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

3.  Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.

Authors:  A A Sima; A Prashar; W X Zhang; S Chakrabarti; D A Greene
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

4.  The reproducibility and sensitivity of sural nerve morphometry in the assessment of diabetic peripheral polyneuropathy.

Authors:  A A Sima; M B Brown; A Prashar; S Chakrabarti; C Laudadio; D A Greene
Journal:  Diabetologia       Date:  1992-06       Impact factor: 10.122

5.  A defect in sodium-dependent amino acid uptake in diabetic rabbit peripheral nerve. Correction by an aldose reductase inhibitor or myo-inositol administration.

Authors:  D A Greene; S A Lattimer; P B Carroll; J D Fernstrom; D N Finegold
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  Regression of diabetic complications by islet transplantation in the rat.

Authors:  A Remuzzi; R Cornolti; R Bianchi; M Figliuzzi; C Porretta-Serapiglia; N Oggioni; V Carozzi; L Crippa; F Avezza; F Fiordaliso; M Salio; G Lauria; R Lombardi; G Cavaletti
Journal:  Diabetologia       Date:  2009-09-30       Impact factor: 10.122

Review 7.  Diabetic neuropathy in the elderly.

Authors:  A A Sima; D A Greene
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

8.  Long-term suppression of postprandial hyperglycaemia with acarbose retards the development of neuropathies in the BB/W-rat.

Authors:  A A Sima; S Chakrabarti
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

Review 9.  Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.

Authors:  Anders A F Sima
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.

Authors:  M Kamijo; P V Cherian; A A Sima
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.